MLYS: Lorundrostat nears approval with strong data, broad market prep, and a focus on parity access
Lorundrostat is positioned for a December PDUFA, with robust clinical data supporting its use in third- and fourth-line hypertension. Commercial preparations, payer engagement, and a parity access strategy are in place, with significant market potential and ongoing R&D planned.Based on Mineralys Th…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.